pharma funding
Jan 05, 2018
Business Cocktail
Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be used to promote nonopioid pain drug candidate CNTX-4975 into a phase 3 trial with patients suffering from knee osteoarth...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
